The Acyl-coenzyme a: Cholesterol acyltransferase inhibitor ci-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice

Journal of Neuropathology and Experimental Neurology

Volumn 69, Issue 8, 2010, Pages 777-788

  Huttunen, Henri J ^a,b,c   Havas, Daniel ^d   Peach, Camilla ^a,b   Barren, Cory ^a,b   Duller, Stephan ^d   Xia, Weiming ^e   Frosch, Matthew P ^b   Hutter Paier, Birgit ^d   Windisch, Manfred ^d   Kovacs, Dora M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MassGeneral Institute for Neurodegenerative Disease   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d JSW Life Sciences GmbH   (Austria)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer disease; Cholesterol transport; Glia; Lipids; Neurodegeneration; Transgenic.

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ACYL COENZYME A; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BRAIN EXTRACT; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; THIOFLAVINE;

AGED; AMYLOID NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HIPPOCAMPUS; HUMAN; MICROGLIA; MOUSE; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE;

ACETATES; AGING; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOSIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; PYRIDINES; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS;

EID: 77955469334     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181e77ed9     Document Type: Article

References (61)

1. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005;115:1121-1129
2. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-372
3. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008;451:720-724
4. Haass C. Take fiveVBACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004;23:483-488
5. Wilcock DM, DiCarlo G, Henderson D, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003;23:3745-3751
6. Jankowsky JL, Slunt HH, Gonzales V, et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med 2005;2:e355
7. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004;41:7-10
8. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: The cholesterol connection. Nat Neurosci 2003;6:345-351
9. Puglielli L, Konopka G, Pack-Chung E, et al. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 2001;3:905-912
10. Huttunen HJ, Greco C, Kovacs DM. Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett 2007;581:1688-1692
11. Hutter-Paier B, Huttunen HJ, Puglielli L, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004;44:227-238
12. Bryleva EY, Rogers MA, Chang CC, et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci\USA 2010; 107:3081-3086
13. Llaverias G, Laguna JC, Alegret M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc Drug Rev 2003;21:33-50
14. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004;110:3372-3377
15. Rockenstein E, Mallory M, Mante M, et al. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 2001;66:573-582
16. Mizoguchi T, Edano T, Koshi T. A method of direct measurement for the enzymatic determination of cholesteryl esters. J Lipid Res 2004;45:396-401
17. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001;21:372-381
18. Alegret M, Llaverias G, Silvestre JS. Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs. Methods Find Exp Clin Pharmacol 2004;26:563-586
19. DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002;81:229-236
20. Murphy MP, Beckett TL, Ding Q, et al. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 2007;27:301-311
21. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-32738
22. Kim WS, Weickert CS, Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 2008;104:1145-1166
23. Wahrle SE, Jiang H, Parsadanian M, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008;118:671-682
24. Kim WS, Rahmanto AS, Kamili A, et al. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem 2007;282: 2851-2861
25. Tansley GH, Burgess BL, Bryan MT, et al. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J Lipid Res 2007;48:1022-1034
26. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid A-peptide deposition. Nat Genet 1997;17:263-264
27. Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 2006;12:1005-1015
28. Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 1989;2:420-436
29. Benzing WC, Wujek JR, Ward EK, et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 1999; 20:581-589
30. Dudal S, Krzywkowski P, Paquette J, et al. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging 2004;25:861-871
31. Oddo S, Caccamo A, Kitazawa M, et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003;24:1063-1070
32. Sotgiu S, Musumeci S, Marconi S, et al. Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer's disease brains. J Neuroimmunol 2008;197:70-73
33. Ito D, Imai Y, Ohsawa K, et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 1998;57:1-9
34. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci\USA 2001;98: 5856-5861
35. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001;8:890-899
36. Park IH, Hwang EM, Hong HS, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003;24:637-643
37. Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloidYinduced microglial inflammatory responses. J Neurosci 2005;25:299-307
38. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-1402
39. Menge T, Hartung HP, Stuve O. StatinsVa cure-all for the brain? Nat Rev Neurosci 2005;6:325-331
40. Jones RW, Kivipelto M, Feldman H, et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimers Dement 2008;4:145-153
41. Huttunen HJ, Peach C, Bhattacharyya R, et al. Inhibition of acyl-coenzyme A:cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J 2009;23:3819-3828
42. Pedrini S, Carter TL, Prendergast G, et al. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoSMed 2005;2:e18
43. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-FcYmediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002;22:7873-7878
44. DiCarlo G, Wilcock D, Henderson D, et al. Intrahippocampal LPS injections reduce Abeta load in APP + PS1 transgenic mice. Neurobiol Aging 2001;22:1007-1012
45. Herber DL, Roth LM, Wilson D, et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004;190:245-253
46. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 2004;18:323-325
47. Barten DM, Guss VL, Corsa JA, et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005;312:635-643
48. Best JD, Smith DW, Reilly MA, et al. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 2007;320:552-558
49. Garcia-Alloza M, Subramanian M, Thyssen D, et al. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener 2009;4:19
50. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-8377
51. Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-3040
52. Antalis CJ, Arnold T, Lee B, et al. Docosahexaenoic acid is a substrate for ACAT1 and inhibits cholesteryl ester formation from oleic acid in MCF-10A cells. Prostaglandins Leukot Essent Fatty Acids 2009;80: 165-171
53. Theuns J, Brouwers N, Engelborghs S, et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 2006;78:936-946
54. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-26
55. Lott IT, Head E. Down syndrome and Alzheimer's disease: A link between development and aging. Ment Retard Dev Disabil Res Rev 2001;7:172-178 (Pubitemid 32843808)
56. Salehi A, Delcroix JD, Belichenko PV, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006;51:29-42
57. Jiang Y, Mullaney KA, Peterhoff CM, et al. Alzheimer's-related endosome dysfunction in Down syndrome is A{beta}-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci\USA 2010;107:1630-1635
58. Cataldo AM, Barnett JL, Pieroni C, et al. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased betaamyloidogenesis. J Neurosci 1997;17:6142-6151
59. Cataldo AM, Peterhoff CM, Troncoso JC, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am J Pathol 2000;157:277-286
60. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-639
61. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-93